Robinson Koilpillai, MD
Family Medicine · Winter Haven, FLNPI 1861499931
Payments from drug & device makers
Across 1,797 payments — averaging $5030.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$7.1M
- Eli Lilly$493K
- Lexicon Pharmaceuticals, Inc.$378K
- Sumitomo Pharma America, Inc.$316K
- Alnylam Pharmaceuticals Inc.$304K
- Novo Nordisk AS$240K
- plus $168K from 29 others
Across 2 payments — averaging $1099.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
What the payments were for
- Food & beverage$3,926100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 345 | $7,141,812 |
| Eli Lilly | 16 | $492,527 |
| Lexicon Pharmaceuticals, Inc. | 27 | $377,898 |
| Sumitomo Pharma America, Inc. | 43 | $316,153 |
| Alnylam Pharmaceuticals Inc. | 412 | $303,773 |
| Novo Nordisk AS | 725 | $239,933 |
| Urovant Sciences Inc | 10 | $104,531 |
| AstraZeneca | 39 | $35,892 |
| Amgen | 21 | $20,011 |
| Pfizer | 21 | $5,407 |
| Boehringer Ingelheim | 29 | $552 |
| AbbVie(2 entities) | 27 | $478 |
| Novo Nordisk | 16 | $296 |
| GSK | 10 | $190 |
| Bayer | 9 | $178 |
| Eisai Inc. | 5 | $113 |
| Novartis | 6 | $113 |
| Lilly USA, LLC | 6 | $111 |
| Abbott | 4 | $82 |
| Daiichi Sankyo Inc. | 4 | $73 |
| Biohaven Pharmaceuticals, Inc. | 3 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $66 |
| Merck | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Antares Pharma, Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 1 | $23 |
| Biogen | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
How this compares
$9,040,551 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 170 | $162,581 |
| OzempicSemaglutide | 128 | $144,206 |
| JardianceEmpagliflozin | 138 | $142,175 |
| MounjaroTirzepatide | 73 | $90,074 |
| XareltoRivaroxaban | 58 | $54,788 |
| TrulicityDulaglutide | 42 | $42,915 |
| ProliaDenosumab | 19 | $33,154 |
| Repatha SureclickEvolocumab | 42 | $29,631 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 97 | $21,464 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $19,207 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $17,419 |
| JanuviaSitagliptin Phosphate | 11 | $16,001 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $15,395 |
| GemtesaVibegron | 18 | $14,018 |
| LinzessLinaclotide | 17 | $11,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5,407 | $162,581170 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $552 | $160,119169 claims |
| Novo NordiskOzempic | $296 | $144,206128 claims |
| Lilly USA, LLCMounjaro, Trulicity | $111 | $132,990115 claims |
| Johnson & JohnsonXarelto | $17 | $54,78858 claims |
| GSKShingrix, Trelegy Ellipta, Arexvy | $190 | $49,589151 claims |
| AmgenProlia | $20,011 | $33,15419 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $35,892 | $26,19361 claims |
| MerckJanuvia | $43 | $16,00111 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $316,153 | $14,01818 claims |
| AbbVieLinzess | $478 | $11,17917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Winter Haven
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.